BDA-366 is a selective antagonist of the liver X receptor (LXR), specifically targeting LXRβ. It has been investigated for its potential in modulating lipid metabolism and inflammation, making it a candidate for research in metabolic disorders such as atherosclerosis and non-alcoholic fatty liver disease (NAFLD). Unlike full LXR agonists, which can increase triglyceride levels, BDA-366 offers a more favorable profile by inhibiting specific LXR-mediated pathways without promoting lipogenesis. This property makes it valuable in preclinical studies focused on cardiovascular health and metabolic syndrome. Additionally, BDA-366 has shown promise in cancer research, particularly in leukemia and prostate cancer models, where LXR signaling plays a role in cell proliferation and survival. Its ability to induce apoptosis in cancer cells without activating lipogenic genes highlights its therapeutic potential as a targeted agent in oncology.